Skip to content
DataLookout
Menu

APTBCyNCT07238712

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Dec 10, 2026 to Dec 10, 2027 Show 6 more changesShow less
    • Eligibility criteria expanded, about 17 words
    • Enrollment closed, study ongoing
    • Enrollment increased: 60 → 80 participants
    • Secondary endpoints: details revised at 1 of 9 entries
    • Site details revised
    • Publications: details revised at 1 of 1 entry
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Overall survival analysis
Timeframe: 2 years

Secondary (9)

Incidence of secondary hemophagocytic lymphohistiocytosis
Incidence of HSCT-associated adverse events (safety and toxicity)
Infectious complications, including analysis of severe bacterial, fungal and viral infections incidence
Incidence of acute GVHD grade II-IV
Incidence of moderate and severe chronic GVHD
Show 4 moreShow less
Non-relapse mortality analysis
Relapse rate analysis
Event-free survival analysis
GVHD-event-free survival analysis

Arms and interventions

Experimental: Test cohort 1 - ruxolitinibExperimental

Days +3 through +4: Bendamustine 50 mg/m2 iv x 2 days; Days +3 through +4: Cyclophosphamide 25 mg/kg iv x 2 days; Days -1 through +21: ruxolitinib 10 mg/kg/day p.o.; mycophenolate mofetil Days +5 through +35 30 mg/kg/day p.o.; Days +5 through +100: Tacrolimus 0.03 mg/kg/day with further correction by concentration

Test cohort 2 - abataceptExperimental

Days +3 through +4: Bendamustine 50 mg/m2 iv x 2 days; Days +3 through +4: Cyclophosphamide 25 mg/kg iv x 2 days; Days -1 through +21: ruxolitinib 10 mg/kg/day p.o.; mycophenolate mofetil Days +5 through +35 30 mg/kg/day p.o.; Days +5 through +100: Tacrolimus 0.03 mg/kg/day with further correction by concentration

Experimental: Expansion cohortExperimental

Days +3 through +4: Bendamustine 50 mg/m2 iv x 2 days; Days +3 through +4: Cyclophosphamide 25 mg/kg iv x 2 days; Days -1,+5, +14, +21 abatacept 10 mg/kg/day i.v.; Days +5 through +100: Tacrolimus 0.03 mg/kg/day with further correction by concentration

Drugs: Ruxolitinib, Abatacept (Orencia)

Sites

1 site in 1 country

  • Pavlov UniversitySaint Petersburg, Russia